Dexverapamil
Term · Oncology and biomedicine · MLC-T-ONC-013018
The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil.
| Identifier | MLC-T-ONC-013018 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | R verapamil; R-verapamil; R-Verapamil Hydrochloride |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013018",
"term": "Dexverapamil",
"field": "Oncology and biomedicine",
"definition": "The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil.",
"synonyms": [
"R verapamil",
"R-verapamil",
"R-Verapamil Hydrochloride"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dexverapamil/"
}
Record 5,905 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.